MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MoonLake Immunotherapeutics
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$9.75+0.20 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $720.67M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
MoonLake Immunotherapeutics has not reported a dividend
No dividend per share appears in MoonLake Immunotherapeutics's annual filings since fiscal 2020.